Updated: Dec 29, 2008
Giant cell tumor of the bone is a relatively uncommon tumor that is characterized by the presence of multinucleated giant cells. This type of tumor is usually regarded as benign. In most patients, giant cell tumors have an indolent course, but they can recur locally in as many as 50% of cases. Metastasis to the lungs may occur.
Cooper first reported giant cell tumors in the 18th century; in 1940, Jaffe and Lichtenstein defined giant cell tumor more strictly to distinguish it from other tumors. Giant cell tumors usually occur de novo but may also occur as a rare complication of Paget disease of the bone.
Related eMedicine topics:
Giant Cell Tumor (Orthopedic Surgery)
Paget Sarcoma
Benign Skull Tumors
Skull Base Tumors
Bone Metastases
Giant cell tumor of the bone accounts for 4-5% of primary bone tumors and 18.2% of benign bone tumors. The incidence is increased in patients with Paget disease of the bone, in which giant cell tumor is a rare neoplastic complication. Giant cell tumor is a rare complication compared with Paget sarcoma,1 which has an incidence of sarcomatous change of <5%.
A slight female predominance is noted; approximately 50-57% of cases involve female patients.
Typically, giant cell tumors occur in skeletally mature patients aged 20-40 years. The incidence peaks in those aged 20-30 years.
Natural history and presentation
Most giant cell tumors (60%) occur in the long bones, and almost all are located at the articular end of the bone (see Image below and Image 5 in Multimedia). Metaphyseal involvement may occur in skeletally immature patients. Common sites include the proximal tibia, distal femur, distal radius, and proximal humerus, although giant cell tumors have also been reported to occur in the pubic bone, calcaneus, and feet.
On cut sections, necrosis and blood-filled spaces are commonly seen. Intact resected specimens of giant cell tumor are rare because most patients are treated by curettage. Grossly, the curettage material is soft, friable, and dark brown. Although called giant cell tumor, the basic proliferating cell is the background mononuclear stromal cell,5 in which the characteristic osteoclastlike giant cells are uniformly distributed (see Image below and Image 1 in Multimedia). The origin of these mononuclear cells is not fully known, but they are believed to be derived from primitive mesenchymal stem cells or cells of a histiocytic macrophage origin.
Although a typical giant cell tumor of the bone is easy to diagnose, a few histologic variants are commonly seen. Small foci of aneurysmal bone cysts are common in giant cell tumor (see Image below and Image 2 in Multimedia).
Giant cell reparative granuloma is a benign reparative lesion that affects the small bones of the hands and feet. It is histologically similar to giant cell tumors of bone. Other primary bone tumors that contain osteoclastlike giant cells include chondroblastoma, chondromyxoid fibroma, and giant cell osteosarcoma.
The radiographic appearance of giant cell tumors is often characteristic.
Magnetic resonance imaging (MRI) is sensitive for the detection of soft-tissue changes, intra-articular extension, and marrow changes. MRI is the best method for assessing subchondral breakthrough and extension of tumor into an adjacent joint. Its diagnostic accuracy is high, especially when MRIs are interpreted in conjunction with plain radiographs.
Computed tomography (CT) scans and bone scans are usually less useful than other examinations.
On radiographs, typical giant cell tumors are usually easily distinguished from other bone tumors. Giant cell tumors are lytic, subarticular, and eccentric, and they are often lacking a sclerotic rim; however, unusual variants may make the radiographic diagnosis difficult.
The disadvantages of MRI are its relatively high cost and limited availability. In addition, some patients experience claustrophobia during the examination and may require sedation. MRI is also contraindicated in patients with cardiac pacemakers, orbital foreign bodies, and noncompatible aneurysmal clips.
Aneurysmal Bone Cyst
Chondroblastoma
Hyperparathyroidism, Primary
Telangiectatic or fibrogenic variants of osteosarcoma
Malignant fibrous histiocytoma (bone)
Metastasis
Plasmacytoma
The most important radiographic findings of giant cell tumor are the location of the tumor, its lytic nature, and the lack of a host response.
Typically, giant cell tumors are expansile, osteolytic, radiolucent lesions without sclerotic margins and usually without a periosteal reaction. Septa may be seen in the lesion in 33-57% of patients (see Image below and Image 10 in Multimedia); these represent nonuniform growth of the tumor rather than true septa. The tumors are typically in the range of 5-7 cm in diameter when they are discovered.
The degree of confidence is high for radiography in the appendicular skeleton. In the spine, the degree of diagnostic confidence is not high, as giant cell tumors usually cannot be differentiated from other types of tumors. Tumors in the sacrum are recognizable, and these may be diagnosed on the basis of their appearance and location.
Unusual forms of certain tumors may mimic giant cell tumors.
Telangiectatic or fibrogenic variants of osteosarcoma may not produce visible ossifications or calcifications. These variants may be eccentric and may extend to the subarticular surface, mimicking a giant cell tumor.
Malignant fibrous histiocytomas occur in a similar age group and can also mimic a giant cell tumor.
Brown tumors of hyperparathyroidism are well known in the differential diagnosis of giant cell tumors.
Chondroblastomas may be mistaken for giant cell tumors because of their subarticular location; however, careful review of the radiographs usually reveals that the epicenter lies in the epiphysis rather than in the metaphysis. The presence of chondroid calcifications further supports the diagnosis of chondroblastoma.
Aneurysmal bone cysts may be only slightly expansile in the early stages, and they can extend to the subarticular cortex, mimicking a giant cell tumor. These cysts usually occur in younger patients. Approximately 29% of aneurysmal bone cysts are reported to be associated with some other solid bone lesion, 39% of which are giant cell tumors.
CT findings are similar to radiographic findings (see Images below and Image 12 in Multimedia) for giant cell tumor of bone.
The degree of confidence is high when CT is used in conjunction with radiography. CT does not usually add much diagnostic information to the radiographic results. CT scans are more useful in complex-shaped bones, such as the vertebrae or pelvic bones, because the details of the lesion may not be depicted well on radiographs (see Images below and Images 14-16 in Multimedia). CT is also useful in surgical planning.
On T1-weighted images, giant cell tumors may show heterogeneous or homogeneous signal intensity characteristics. The signal intensity is usually low or intermediate, but areas of high signal-intensity, caused by recent hemorrhage, may be noted.7
On T2-weighted images, heterogeneous low-to-intermediate signal intensity is seen in solid areas of the tumor (see Image below and Image 17 in Multimedia). Areas of low signal intensity may be exaggerated on T2-weighted spin-echo images, and these may be even more exaggerated on gradient-echo weighted images because of the presence of hemosiderin. Hemosiderin is detected in more than 63% of giant cell tumors, and its presence is probably the result of extravasated red blood cells coupled with the phagocytic function of the tumor cells.
Cystic areas are common and are seen as areas of high signal intensity on T2-weighted images. Fluid-fluid levels may be seen (see Image below and Image 18 in Multimedia). Peritumoral edema is uncommon in the absence of a fracture. The tumor is usually heterogeneously enhancing with the intravenous administration of contrast material.
The degree of confidence of MRI is high for imaging the appendicular skeleton. The MRI findings for giant cell tumors of the lower spine may overlap with those of other tumors, such as osteoblastoma, aneurysmal bone cyst, and metastasis.
MRI is sensitive for the detection of soft-tissue changes, intra-articular extension, and marrow changes. MRI is the best method for assessing subchondral breakthrough and the extension of tumor into an adjacent joint. Its diagnostic accuracy is high, especially when MRIs are interpreted in conjunction with plain radiographs.
In the spine, tumors such as osteoblastoma, aneurysmal bone cyst, and metastasis may be found in the same location as giant cell tumors, and they may have overlapping MRI characteristics.
Uptake in giant cell tumors is usually diffuse in all phases. The degree of uptake is not correlated with the grade of the tumor or the malignancy. Bone scanning is not usually required in the evaluation of a giant cell tumor, except for the rare case in which multicentric giant cell tumors are suspected.
The degree of confidence is low with nuclear medicine studies. Giant cell tumors cannot be confidently differentiated from other tumors and diseases by using bone scans alone.
Tracer uptake is not specific for giant cell tumors.
Angiography is not usually required in the evaluation of a giant cell tumor. Neovascularity is demonstrated in 80% of giant cell tumors, along with an intense, inhomogeneous capillary blush. Unfortunately, overlap in the angiographic features of malignant bone tumors, benign tumors, and nonneoplastic lesions precludes the use of angiography in making the differential diagnosis.
Although angiography can be used to assess the intraosseous and extraosseous extent of a tumor, which is useful in planning surgery, MRI has largely replaced angiography in surgical planning.
Preoperative embolization may be performed as a surgical adjunct to diminish bleeding and facilitate resection in highly vascular tumors. Complete removal of a tumor’s extraosseous component is mandatory to prevent local recurrence (see Image below and Image 19 in Multimedia), which may be difficult in a highly vascularized tumor.
Angiographic features are not diagnostic of giant cell tumor.
Hoch B, Hermann G, Klein MJ, Abdelwahab IF, Springfield D. Giant cell tumor complicating Paget disease of long bone. Skeletal Radiol. Apr 14 2007;[Epub ahead of print]. [Medline].
Swanger R, Maldjian C, Murali R, Tenner M. Three cases of benign giant cell tumor with unusual imaging features. Clin Imaging. Sep-Oct 2008;32(5):407-10. [Medline].
Salerno M, Avnet S, Alberghini M, Giunti A, Baldini N. Histogenetic characterization of giant cell tumor of bone. Clin Orthop Relat Res. Sep 2008;466(9):2081-91. [Medline].
Balke M, Ahrens H, Streitbuerger A, Koehler G, Winkelmann W, Gosheger G, et al. Treatment options for recurrent giant cell tumors of bone. J Cancer Res Clin Oncol. Jan 2009;135(1):149-58. [Medline].
Ghert M, Simunovic N, Cowan RW, Colterjohn N, Singh G. Properties of the stromal cell in giant cell tumor of bone. Clin Orthop Relat Res. Jun 2007;459:8-13. [Medline].
Lanza A, Laino L, Rossiello L, Perillo L, Ermo AD, Cirillo N. Clinical Practice: Giant Cell Tumour of the Jaw Mimicking Bone Malignancy on Three-Dimensional Computed Tomography (3D CT) Reconstruction. Open Dent J. 2008;2:73-7. [Medline].
Sirikulchayanonta V, Jaovisidh S. Including MIR of a primary bone leiomyosarcoma that radiologically mimics a giant cell tumor. J Med Assoc Thai. Feb 2008;91(2):244-8. [Medline].
Aoki J, Tanikawa H, Ishii K, et al. MR findings indicative of hemosiderin in giant-cell tumor of bone: frequency, cause, and diagnostic significance. AJR Am J Roentgenol. Jan 1996;166(1):145-8. [Medline].
Biscaglia R, Bacchini P, Bertoni F. Giant cell tumor of the bones of the hand and foot. Cancer. May 1 2000;88(9):2022-32. [Medline].
Cai G, Ramdall R, Garcia R, Levine P. Pulmonary metastasis of giant cell tumor of the bone diagnosed by fine-needle aspiration biopsy. Diagn Cytopathol. Jun 2007;35(6):358-62. [Medline].
Dahlin DC. Giant-cell tumor of vertebrae above the sacrum: a review of 31 cases. Cancer. Mar 1977;39(3):1350-6. [Medline].
Feldman F, Casarella WJ, Dick HM, Hollander BA. Selective intra-arterial embolization of bone tumors. A useful adjunct in the management of selected lesions. Am J Roentgenol Radium Ther Nucl Med. Jan 1975;123(1):130-9. [Medline].
Gebhart M, Vandeweyer E, Nemec E. Paget''s disease of bone complicated by giant cell tumor. Clin Orthop. Jul 1998;(352):187-93. [Medline].
Goldenberg RR, Campbell CJ, Bonfiglio M. Giant-cell tumor of bone. An analysis of two hundred and eighteen cases. J Bone Joint Surg Am. Jun 1970;52(4):619-64. [Medline].
Kransdorf MJ, Sweet DE, Buetow PC, et al. Giant cell tumor in skeletally immature patients. Radiology. Jul 1992;184(1):233-7. [Medline].
Manaster BJ, Doyle AJ. Giant cell tumors of bone. Radiol Clin North Am. Mar 1993;31(2):299-323. [Medline].
Meyers SP, Yaw K, Devaney K. Giant cell tumor of the thoracic spine: MR appearance. AJNR Am J Neuroradiol. May 1994;15(5):962-4. [Medline].
Parman LM, Murphey MD. Alphabet soup: cystic lesions of bone. Semin Musculoskelet Radiol. 2000;4(1):89-101. [Medline].
Potter HG, Schneider R, Ghelman B, et al. Multiple giant cell tumors and Paget disease of bone: radiographic and clinical correlations. Radiology. Jul 1991;180(1):261-4. [Medline].
Prando A, deSantos LA, Wallace S, Murray JA. Angiography in giant-cell bone tumors. Radiology. Feb 1979;130(2):323-31. [Medline].
Siebenrock KA, Unni KK, Rock MG. Giant-cell tumour of bone metastasising to the lungs. A long-term follow-up. J Bone Joint Surg Br. Jan 1998;80(1):43-7. [Medline].
Smith J, Wixon D, Watson RC. Giant-cell tumor of the sacrum. Clinical and radiologic features in 13 patients. J Can Assoc Radiol. Mar 1979;30(1):34-9. [Medline].
Sung HW, Kuo DP, Shu WP, et al. Giant-cell tumor of bone: analysis of two hundred and eight cases in Chinese patients. J Bone Joint Surg Am. Jun 1982;64(5):755-61. [Medline].
Tan BS, Doust BD, Mansberg VJ. Multicentric giant cell tumour and phaeochromocytoma. Australas Radiol. Aug 1996;40(3):360-3. [Medline].
Wallace S, Granmayeh M, deSantos LA, et al. Arterial occlusion of pelvic bone tumors. Cancer. Jan 1979;43(1):322-8. [Medline].
giant cell tumor, osteoclastoma, multinucleated giant cells, Paget disease, aneurysmal bone cysts, osteoclastlike giant cells
Lesley-Ann Goh, MBBS, FRCR, Consultant, Department of Diagnostic Radiology, National University Hospital
Disclosure: Nothing to disclose.
Wilfred CG Peh, MD, MBBS, FRCP(Glasg), FRCP(Edin), FRCR, Clinical Professor, Faculty of Medicine, National University of Singapore; Senior Consultant Radiologist, Alexandra Hospital, Singapore
Wilfred CG Peh, MD, MBBS, FRCP(Glasg), FRCP(Edin), FRCR is a member of the following medical societies: American Roentgen Ray Society, British Institute of Radiology, International Skeletal Society, Radiological Society of North America, Royal College of Physicians, and Royal College of Radiologists
Disclosure: Nothing to disclose.
Tony WH Shek, MBBS, FRCPA, FHKCPath, FHKAM, Honorary Clinical Assistant Professor, Department of Pathology, University of Hong Kong
Disclosure: Nothing to disclose.
Giuseppe Guglielmi, MD, Associate Professor of Radiology, Department of Radiology, Scientific Institute Hospital
Disclosure: Nothing to disclose.
Bernard D Coombs, MB, ChB, PhD, Consulting Staff, Department of Specialist Rehabilitation Services, Hutt Valley District Health Board, New Zealand
Disclosure: Nothing to disclose.
Murali Sundaram, MBBS, FRCR, FACR, Consulting Staff, Department of Diagnostic Radiology, The Cleveland Clinic Foundation
Disclosure: Nothing to disclose.
Robert M Krasny, MD, Consulting Staff, Department of Radiology, The Angeles Clinic and Research Institute
Robert M Krasny, MD is a member of the following medical societies: American Roentgen Ray Society and Radiological Society of North America
Disclosure: Nothing to disclose.
Felix S Chew, MD, MBA, EdM, Professor, Department of Radiology, Vice Chairman for Radiology Informatics, Section Head of Musculoskeletal Radiology, University of Washington
Felix S Chew, MD, MBA, EdM is a member of the following medical societies: American Roentgen Ray Society, Association of University Radiologists, and Radiological Society of North America
Disclosure: Nothing to disclose.